The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy

Abstract

These data suggest that hyperprolactinaemia is associated with insulin resistance related to increased BMI and low-grade inflammation independently of BMI. Short-term cabergoline therapy can reduce the inflammatory markers.